• 5 Reasons This Stock Can Surpass Its Sector

    By Lee Samaha - August 7, 2013 | Tickers: COV, GE, JNJ

    It’s been a tricky market for medical device companies in 2013, but you wouldn’t know it from Covidien’s (NYSE: COV) share price performance.

    The stock is up nearly 23% this year, even while companies like Johnson & Johnson(NYSE: JNJ) have disclosed lower-than-expected growth in surgical procedures. Moreover, the spinoff of Covidien's pharmaceuticals business (to be called Mallinckrodt) turns it into a pure-play medical device company. Why more »

  • This Acquisition Will Improve Abbott's Business

    By Kanak Kanti - July 29, 2013 | Tickers: ABT, BCR, COV

    Abbott Laboratories' (NYSE: ABT) bid to acquire IDEV Technologies by end-2013 will strengthen the former’s medical devices (Abbott Vascular) business especially in stent offerings for pulmonary arterial diseases (PAD). Abbott Vascular represents roughly 14% of Abbott's total sales, and that mostly comprises various types of drug eluting stents (DES). However, PAD is another very important type of stent that Abbott does not cover at present. IDEV's expertise more »

  • Is This Health-Care Giant Still a Good Value?

    By Lee Samaha - July 23, 2013 | Tickers: COV, JNJ, COO, VAR

    Investors in health-care giant Johnson & Johnson (NYSE: JNJ) have been rewarded with a 30% share price rise in the last year. The health-care giant remains a go-to choice for investors seeking a relatively recession-proof stock with a decent dividend. However, investors need to ask themselves a few questions about its recent results: Can this share price run continue?  Does Johnson & Johnson still provide compelling value?  And what are the key more »

  • 3 Medical Instrument and Supply Companies You Don’t Want to Miss

    By Shweta Dubey - July 10, 2013 | Tickers: BAX, BDX, COV

    The U.S. is the world’s leading medical device manufacture. Becton Dickinson (NYSE: BDX), Baxter International (NYSE: BAX), Covidien (NYSE: COV) are amongst the top ten manufactures for medical devices. The U.S. medical device industry is expected to grow at CAGR 6.3% for the period of 2011-2018. The medical device market revenue is projected to increase from $102.1 billion in 2011 to $156.8 billion by more »

  • When Should Investors Buy This New Pharma Company?

    By Mike Thiessen - July 10, 2013 | Tickers: BDX, COV, MNK

    After nearly two years of waiting, Covidien (NYSE: COV) investors were finally treated to the latest in a long line of pharmaceutical and medical device spin-offs. As of July 1, 2013, Dublin-based Covidien and St. Louis-based Mallinckrodt Pharmaceuticals (NYSE: MNK) had formally split into separate companies that traded independently of one another. Although the companies have thus far experienced divergent share-price performance, this development has been welcomed by investors on more »

  • 3 Companies That May Help You Living Longer

    By Damian Illia - July 5, 2013 | Tickers: BAX, COV, RMD

    An aging western society has opened many opportunities for firms involved in pharmaceuticals, medical instruments and supplies. The following three: ResMed (NYSE: RMD), Covidien (NYSE: COV), and Baxter International (NYSE: BAX) have created a small economic moats for themselves, are fair valued, and hold positive future outlooks. Let us find why, despite their troubled present, their futures may be brighter.

    Already dreaming more profits

    Focused on sleep disorders, medical instruments more »

  • Three Interesting New Buys from Leon Cooperman

    By Anh HOANG - May 29, 2013 | Tickers: COV, LYB, OXY

    Leon Cooperman, the founder and chairman of Omega Advisors, is a very successful value investor. With nearly $6.5 billion in total assets under management, he owns around 81 stocks in his portfolio. In the first quarter of 2013 he initiated long positions in Occidental Petroleum (NYSE: OXY), LyondellBasell Industries NV (NYSE: LYB) and Covidien PLC (NYSE: COV).

    While Occidental Petroleum and LyondellBasell each accounted for 1.2% of his more »

  • Value Investors First Pacific Advisors: What’s It Bullish On?

    By Meena Krishnamsetty - May 28, 2013 | Tickers: AON, COV, CVS

    Hedge funds are required to file 13F forms with the Securities and Exchange Commission after the end of each calendar quarter. One of the funds we track is First Pacific Advisors, managed by Robert Rodriguez and Steven Romick. We will review the five largest equity holdings of First Pacific, via its first quarter 13F. The original filing can be found here, and it’s important to note that piggybackers can more »

  • Does the Healthcare Industry mean Stability?

    By tarun bachhawat - May 14, 2013 | Tickers: BDX, COV, NVO

    A leading medical technology company, Becton, Dickinson and Company's (NYSE: BDX) earnings were better than expected. It is one of the few medical companies that is able to deliver organic growth in a challenged healthcare industry. 

    A decent quarter
    Becton Dickinson reported revenue of $2 billion for the quarter and profit of $275.6 million, beating Wall Street's estimate by $0.04 per share. Revenue from sales in more »
  • This Medical Company Is Not Cheap

    By Anh HOANG - May 2, 2013 | Tickers: BDX, BCR, COV

    Recently, Covidien (NYSE: COV) witnessed a significant decline of nearly 7% after it announced sluggish second-quarter earnings. Even after the drop, Covidien’s share price has gained more than 7.3% since the beginning of the year. The company is currently in the portfolios of several famous investors including Ray Dalio, Steven Cohen, and Paul Tudor Jones. Should we consider a recent drop in its share price as an investment more »

  • Has This Stock Priced in the Near Term Risk?

    By Lee Samaha - April 29, 2013 | Tickers: COV, GE, JNJ, VAR

    One of the peculiar aspects of the market move upwards in 2013 is that the defensives have led the way while the traditionally more economically sensitive areas like technology have lagged. Indeed, anyone trying to construct a balanced portfolio is going to have to deal with the contradiction inherent in only wanting to buy value as well. What happens when the value is mainly within technology and therefore guiding you more »

  • This Healthcare Bellwether Still Has Room to Run

    By Lee Samaha - April 22, 2013 | Tickers: CL, COV, JNJ

    Earnings season is in full swing now and Johnson & Johnson (NYSE: JNJ) was the first of the major health care and consumer products companies to give results. In summary, the numbers were pretty good, but the commentary contained some negatives about the health care industry with regards the medical devices and the volume of surgical procedures. On the whole, it was a net positive for the company and despite the more »

  • Healthcare's Bellwether Still Has Room To Run

    By Lee Samaha - April 16, 2013 | Tickers: CL, COV, JNJ

    Earnings season is in swing now and Johnson & Johnson (NYSE: JNJ) is the first of the major health care and consumer products companies to give results. In summary the numbers were pretty good for the company but the commentary contained some negatives for the health care industry with regards the medical devices marketplace and the volume of surgical procedures. On balance it was a net positive for the company and more »

  • Buybacks Could Keep Up This Stock's Momentum

    By Mike Thiessen - April 2, 2013 | Tickers: COV, MDT, PFE

    Dublin-based pharmaceutical and medical device company Covidien (NYSE: COV) recently announced that it had authorized a share buyback program that could be worth up to $2 billion. This announcement comes just a few months after the company boosted its dividend by more than 15 percent and issued several quarters of solid earnings. To make matters even more interesting, the company appears to be nearing the completion of its long-awaited spin-off more »

  • This Pharma Products Company Is Still A Buy

    By Marshall Hargrave - March 22, 2013 | Tickers: ABC, CAH, COV, MCK, WAG

    Cardinal Health (NYSE: CAH) took a big hit last week, down as much as 8% on the news that its pharmaceutical distribution contract with Walgreen Company (NYSE: WAG) would not be renewed. The agreement is scheduled to expire at the end of August 2013. So is the pull back a buying opportunity, or is the fact that Walgreen accounts for over 20% of Cardinal revenues a reason to run?

    Cardinal more »

  • How to Profit From Increasing Obesity

    By Lee Samaha - March 19, 2013 | Tickers: COV, MCD, NVO, PEP, SNY

    Note: A previous version of this article incorrectly stated the effect of Novo Nordisk's type 2 diabetes treatment. The mistake has been corrected below.

    Funnily enough, I think that long term investors should be investing in the long term. In this article I’m going to discuss obesity, its prevalence and suggest some of the stocks that might be bought and avoided as a consequence.

    Obesity Prevalence

    Everyone loves more »

  • Interesting Medical Spin-Off for Mid-2013

    By Mike Thiessen - March 18, 2013 | Tickers: ABBV, COV, TYC

    Dublin-based medical conglomerate Covidien PLC (NYSE: COV) has confirmed that it plans to complete the spin-off of its pharmaceutical division by the middle of 2013. Although the proposal to create Mallinckrodt Pharmaceuticals was announced more than a year ago, it has been subject to some non-fatal delays along the way. However, these appear to have been resolved. The soon-to-be-independent division has embarked on a major hiring spree and appears poised more »

  • What I've Been Buying and Selling This Quarter (Feb)

    By Lee Samaha - March 5, 2013 | Tickers: CGNX, CL, COV, CREE, WFM

    It’s the start of a new month and time to review quarterly performance and more importantly whether the process of writing investment thoughts out here and on my blog is helping performance or not. It was a decent performance in the quarter, up 12.3% vs. 6.9% for the S&P 500. For the sake of brevity I’m not going into my strategy, but you can find more »

  • Why Healthcare Industry is Such a Rewarding Endeavour!

    By Binu Buvaria - March 3, 2013 | Tickers: COV, JNJ, NVS

    The world’s largest and the most diverse medical devices and diagnostics company, Johnson & Johnson (NYSE: JNJ), is the leading manufacturer of health care products. One of the nation’s most trusted brands lost its consumer's confidence in recent years as the company recalled several of its products, such as children’s Tylenol, artificial hips, and other related products. To overcome this failure, they endorsed research and science, so more »

  • Three Reasons to Worry and One Theme That Can Outperform

    By Lee Samaha - February 22, 2013 | Tickers: ACT, COV, ILMN, LIFE, MYL

    Occasionally some of my friends ask me why I am hedged and market neutral in my investing. My answer is always the same. I invest for the long term, and the macro-environment remains very dangerous right now. I am confident in my ability to pick a portfolio that can outperform the market, but I can’t predict what is going to happen in the global economy, and the evidence is more »

  • Page 1 of 3